Singapore - English - HSA (Health Sciences Authority)

organon singapore pte. ltd. - (ir layer) desloratadine, micronized; (sr layer) pseudoephedrine sulfate - tablet, delayed release - 2.5mg - (ir layer) desloratadine, micronized 2.5mg; (sr layer) pseudoephedrine sulfate 120.0mg

Singapore - English - HSA (Health Sciences Authority)

hyphens pharma pte. ltd. - formoterol fumarate dihydrate - aerosol, metered - 0.012mg/inhalation - formoterol fumarate dihydrate 0.012mg/inhalation

Malta - English - Medicines Authority

ucb pharma sa 60 allee de la recherche, b-1070 brussels, belgium - hydroxyzine hydrochloride - syrup - hydroxyzine hydrochloride 2 mg/ml - psycholeptics

Malta - English - Medicines Authority

ucb pharma sa 60 allee de la recherche, b-1070 brussels, belgium - hydroxyzine hydrochloride - film-coated tablet - hydroxyzine hydrochloride 25 mg - psycholeptics

Malta - English - Medicines Authority

proge farm s.r.l. baluardo la marmora, 4 - 28100 - novara, italy - betamethasone dipropionate - cream - betamethasone dipropionate 0.05 % (w/w) - corticosteroids, dermatological preparations

Malta - English - Medicines Authority

ucb pharma sa - meclozine hydrochloride 25 mg - tablet

United Kingdom - English - myHealthbox

infirst healthcare limited - diphenhydramine hydrochloride, ammonium chloride, levomenthol - oral solution - 14mg/135mg/1.1mg - antihistamines for systemic use - for the oral symptomatic relief of common coughs (such as dry and/or tickly, or troublesome cough) associated with respiratory tract congestion and aids restful sleep.

Ireland - English - HPRA (Health Products Regulatory Authority)

teva b.v. - efavirenz; emtricitabine; tenofovir disoproxil - film-coated tablet - 600 mg/200 mg/245 milligram(s) - antivirals for treatment of hiv infections, combinations; emtricitabine, tenofovir disoproxil and efavirenz

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - diphenhydramine hydrochloride (unii: tc2d6jad40) (diphenhydramine - unii:8gts82s83m) - diphenhydramine hydrochloride 50 mg in 1 ml - diphenhydramine hydrochloride in the injectable form is effective in adults and pediatric patients, other than premature infants and neonates, for the following conditions when diphenhydramine hydrochloride in the oral form is impractical. antihistaminic: for amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after the acute symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated. motion sickness: for active treatment of motion sickness. antiparkinsonism: for use in parkinsonism, when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents. use in neonates or premature infants: this drug should not be used

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - desloratadine (unii: fvf865388r) (desloratadine - unii:fvf865388r), pseudoephedrine sulfate (unii: y9dl7qpe6b) (pseudoephedrine - unii:7cuc9ddi9f) - desloratadine 2.5 mg - clarinex-d® 12 hour extended release tablets is indicated for the relief of the nasal and non-nasal symptoms of seasonal allergic rhinitis, including nasal congestion, in adults and adolescents 12 years of age and older. clarinex-d 12 hour extended release tablets should be administered when the antihistaminic properties of desloratadine and the nasal decongestant properties of pseudoephedrine are desired [see clinical pharmacology (12)] . clarinex-d 12 hour extended release tablets are contraindicated in: - patients with hypersensitivity to any of its ingredients, or to loratadine [see warnings and precautions (5.4) and post-marketing experience (6.2)] - patients with narrow angle glaucoma - patients with urinary retention - patients receiving monoamine oxidase (mao) inhibitor therapy or within fourteen (14) days of stopping such treatment [see drug interactions (7.1)] . - patients with severe hypertension or severe coronary artery disease pregnancy category c: there are no adequate and well-controlled stu